ZIOP - Here's Why Ziopharm Oncology Stock Is Up 18% This Week
Shares of Ziopharm Oncology (NASDAQ: ZIOP) , jumped more than 30% on Tuesday. Shares of the clinical-stage biopharmaceutical company finished Thursday up around 18% from their closing price last Friday. While the company's been quiet, investors were highly encouraged by a handful of insider stock purchases.
Last Friday afternoon, just before Labor Day weekend, Ziopharm disclosed to the Securities and Exchange Commission four direct stock purchases from company insiders. James Huang, a financier of several lucrative life-science ventures including Legend Biotech , raised his stake from a little over 8,000 shares to around 108,000 shares. One of the company's largest shareholders, Robert Postma, bought 75,000 shares pushing his total Ziopharm holdings past 5.45 million shares.
Image source: Getty Images.
For further details see:
Here's Why Ziopharm Oncology Stock Is Up 18% This Week